<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369866">
  <stage>Registered</stage>
  <submitdate>7/01/2016</submitdate>
  <approvaldate>10/02/2016</approvaldate>
  <actrnumber>ACTRN12616000167460</actrnumber>
  <trial_identification>
    <studytitle>Antibiotic Concentration in Critically ill intensive care unit (ICU) patients in Sweden</studytitle>
    <scientifictitle>Antibiotic Concentration in Critically ill ICU-patients in Sweden (ACCIS)</scientifictitle>
    <utrn />
    <trialacronym>ACCIS</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sepsis</healthcondition>
    <healthcondition>Septic shock</healthcondition>
    <healthcondition>Critical illness</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Concentrations of cefotaxime, piperacillin-tazobactam, meropenem, ciprofloxacin, gentamicin, tobramycin, amikacin and vancomycin in the plasma will be assessed upon start of antibiotic therapy, in intensive care patients with suspected or verified infection. Blood samples will be taken twice daily for 3 days. Clinical data with impact on pharmacokinetics as well as microbiological results will be collected.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess if antibiotic concentrations in plasma are lower than those recommended in current international guidelines.</outcome>
      <timepoint>Days 1-3 of antibiotic therapy.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess if antibiotic concentrations in plasma are higher than those recommended in current international guidelines.</outcome>
      <timepoint>Days 1-3 of antibiotic therapy.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To find mechanistic explanations to variations in plasma antibiotic concentration in this group such as variations in renal function (eGFR), liver function (INR), plasma protein levels (plasma albumin), continuous renal replacement therapy (dose) etc.</outcome>
      <timepoint>Days 1-3 antibiotic therapy.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To relate plasma antibiotic concentration to the MIC values of the isolated bacteria from each patient with positive cultures. </outcome>
      <timepoint>Days 1-3 of antibiotic therapy.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Intensive care patient with any severe suspected or verified infection requiring initiation of new antibiotic treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Intermittent hemodialysis
Known pregnancy
Limitations of care</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Descriptive statistics

To show that 10% of the patients have lower plasma antibiotic concentration than current recommendations, at least 16 patients will have to be included for each 8 studied antibiotic agent for an alpha error of 0.05 and beta error of 0.8. Due to the risk of missing data, uneven distribution between groups etc we aim at including 150 patients i.e. 10% more than the sample size suggests.
To counteract uneven distribution between groups, an interim analysis will be performed after the inclusion of 75 patients to ensure that the distribution of patients is similar for the eight antibiotics studied. Inclusion for antibiotics with 16 or more patients included will be terminated.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>True</patientregistry>
    <followup>3</followup>
    <followuptype>Days</followuptype>
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>18/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate>5/07/2017</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>158</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>3/09/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Uppsala university</primarysponsorname>
    <primarysponsoraddress>Department of Surgical Sciences 
Anaesthesiology and Intensive Care 
Uppsala University
Akademiska sjukhuset 
751 85 Uppsala
Sweden

</primarysponsoraddress>
    <primarysponsorcountry>Sweden</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Uppsala-Orebro Regional Research Council</fundingname>
      <fundingaddress>Uppsala-Orebro Regional Research Council
801 88 Gavle
Sweden</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Uppsala university hospital research fund</fundingname>
      <fundingaddress>Akademiska sjukhuset
751 85 Uppsala
Sweden</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Uppsala university hospital</sponsorname>
      <sponsoraddress>Akademiska sjukhuset 
751 85 Uppsala
Sweden
</sponsoraddress>
      <sponsorcountry>Sweden</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Karlstad county hospital</othercollaboratorname>
      <othercollaboratoraddress>Centralsjukhuset i Karlstad
Rosenborgsgatan
652 30 Karlstad
Sweden</othercollaboratoraddress>
      <othercollaboratorcountry>Sweden</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Eskilstuna county hospital</othercollaboratorname>
      <othercollaboratoraddress>Malarsjukhuset
Kungsvagen 34
633 49 Eskilstuna
Sweden</othercollaboratoraddress>
      <othercollaboratorcountry>Sweden</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Vasteras county hospital</othercollaboratorname>
      <othercollaboratoraddress>Vastmanlands sjukhus Vasteras
721 89 Vasteras
Sweden</othercollaboratoraddress>
      <othercollaboratorcountry>Sweden</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Gavle county hospital</othercollaboratorname>
      <othercollaboratoraddress>Gavle sjukhus
Lasarettsvagen 5
803 24 Gavle
Sweden</othercollaboratoraddress>
      <othercollaboratorcountry>Sweden</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Karolinska University Hospital Huddinge</othercollaboratorname>
      <othercollaboratoraddress>Karolinska Universitetssjukhuset Huddinge
Halsovagen, Flemingsberg
141 86 Stockholm
Sweden</othercollaboratoraddress>
      <othercollaboratorcountry>Sweden</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Background
Antibiotic therapy has the major impact on morbidity and mortality in severe sepsis and septic shock (Kumar, Roberts et al. 2006; Bagshaw, Lapinsky et al. 2009). Rapid killing of bacteria is considered important to limit the infection and systemic inflammatory response. Pharmacokinetic data for most antibiotics are obtained in healthy human volunteers.  Hence, it is unclear if adequate antibiotic concentrations in plasma are achieved in critically ill patients with infections, especially on the first day of treatment when benefits of adequate dosed antibiotics are greatest. This is unfortunate, since the outcome in ICU patients depends on early, accurate and adequately dosed antibiotic treatment. Underdosing antibiotics leads to the no or limited effect against infectious agents with the risk of lack of infection control as well as risk of emergence of multi-resistant strains. Overdosing antibiotics increases the risk of toxicity without providing additional benefit. 
There are several reasons for variations in drug concentration in ICU. Large changes in total body water may be seen due to intravenous fluids given during resuscitation (Liu, Thompson et al. 2011). Moreover, changes are seen in plasma protein levels (Investigators, Finfer et al. 2011) permeability between the different compartments, liver function, (Macnab, Macrae et al. 1986) renal function (White, Hassoun et al. 2013) and renal tubular function (Wen, Peng et al. 2011). In addition, critically ill patients treated with continuous renal replacement therapy (CRRT) in severe renal impairment that alters the excretion of the drugs with predominantly renal clearance (Lau, Kronfol et al. 1987).
Thus, to date it is unknown what proportion of the ICU patients have adequate plasma concentrations of antibiotics, whether antibiotic concentrations change during the first days and if the pharmacokinetics of these drugs is affected by the critical illness and / or intensive care.
Hypothesis
Plasma concentrations of antibiotics in ICU patients during the first 72 hours after initiation of treatment are too low to provide adequately dosed antibacterial therapy. 
Method
In a prospective multicenter study, concentrations of cefotaxime, piperacillin-tazobactam, meropenem, ciprofloxacin, gentamicin, tobramycin, amikacin and vancomycin in the plasma will be measured twice daily for 3 days after the initiation of treatment in intensive care patients with suspected infection. Participating centers are: the general ICU, the cardiothoracic ICU and the burns ICU at Uppsala university hospital, and general ICUs at County hospitals in Eskilstuna, Vasteras, Karlstad, and Gavle, as well as the general ICU at Karolinska University Hospital Huddinge. Demographic, clinical, laboratory and microbiological data will be collected.  Antibiotic concentrations in each patient with positive cultures will be compared with the MIC for the isolated bacteria from the same patient.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Regional Ethical Review Board, Uppsala</ethicname>
      <ethicaddress>Drottninggatan 4
753 09 Uppsala
Sweden</ethicaddress>
      <ethicapprovaldate>3/09/2015</ethicapprovaldate>
      <hrec>Dnr 2015/135</hrec>
      <ethicsubmitdate>26/03/2015</ethicsubmitdate>
      <ethiccountry>Sweden</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Miklos Lipcsey</name>
      <address>Department of Surgical Sciences 
Anaesthesiology and Intensive Care 
Uppsala University Hospital
Akademiska sjukhuset 
751 85 Uppsala
Sweden</address>
      <phone>+46 - 18 - 611 96 60</phone>
      <fax />
      <email>miklos.lipcsey@surgsci.uu.se</email>
      <country>Sweden</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Miklos Lipcsey</name>
      <address>Department of Surgical Sciences 
Anaesthesiology and Intensive Care 
Uppsala University Hospital
Akademiska sjukhuset 
751 85 Uppsala
Sweden</address>
      <phone>+46 - 18 - 611 96 60</phone>
      <fax />
      <email>miklos.lipcsey@surgsci.uu.se</email>
      <country>Sweden</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Miklos Lipcsey</name>
      <address>Department of Surgical Sciences 
Anaesthesiology and Intensive Care 
Uppsala University Hospital
Akademiska sjukhuset 
751 85 Uppsala
Sweden</address>
      <phone>+46 - 18 - 611 96 60</phone>
      <fax />
      <email>miklos.lipcsey@surgsci.uu.se</email>
      <country>Sweden</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>